/PSNL
PSNL Stock - Personalis, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$8.55+7.89%
+$0.63 (+7.89%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.70
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.40
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+24.8%upside
Target: $10.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PSNL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.46 – $8.64
TARGET (TP)$10.67
STOP LOSS$7.87
RISK/REWARD1:3.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.00
52W High$11.40
52W Low$2.83
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $84.61M | $73.48M | $65.05M | $85.49M | $78.65M |
| Gross Profit | $26.82M | $18.21M | $13.35M | $31.66M | $20.11M |
| Gross Margin | 31.7% | 24.8% | 20.5% | 37.0% | 25.6% |
| Operating Income | $-68,267,000 | $-109,936,000 | $-115,531,000 | $-65,353,000 | $-42,146,000 |
| Net Income | $-81,284,000 | $-108,296,000 | $-113,315,000 | $-65,226,000 | $-41,280,000 |
| Net Margin | -96.1% | -147.4% | -174.2% | -76.3% | -52.5% |
| EPS | $-1.37 | $-2.25 | $-2.48 | $-1.49 | $-1.20 |
Company Overview
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
75%
Hold / Neutral
1
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish1 Neutral/Bearish
Price Targets
$8
Average Target
↓ 2.5% Downside
Now
$6
Low
$8
Average
$11
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Morgan Stanley | Resumed | Equal Weight | $11 |
| May 15th 2025 | Guggenheim | Initiation | Buy | $6 |
| March 17th 2025 | Craig Hallum | Initiation | Buy | $8 |
| February 6th 2023 | Needham | Upgrade | Buy | - |
Earnings History & Surprises
PSNLBeat Rate
78%
Last 18 quarters
Avg Surprise
+5.7%
EPS vs Estimate
Beats / Misses
14/3
1 met exactly
Latest EPS
$-0.24
Q4 2025
EPS Surprise History
Q1 24
+13.2%
$-0.46vs$-0.53
Q2 24
+40.9%
$-0.26vs$-0.44
Q3 24
+29.4%
$-0.24vs$-0.34
Q4 24
-93.9%
$-0.64vs$-0.33
Q1 25
+28.1%
$-0.23vs$-0.32
Q2 25
+21.7%
$-0.18vs$-0.23
Q3 25
+8.0%
$-0.23vs$-0.25
Q4 25
+14.3%
$-0.24vs$-0.28
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.31 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.28 | $-0.24 | +14.3% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.23 | $-0.18 | +21.7% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.32 | $-0.23 | +28.1% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.33 | $-0.64 | -93.9% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.34 | $-0.24 | +29.4% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.44 | $-0.26 | +40.9% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.53 | $-0.46 | +13.2% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.54 | $-0.51 | +5.6% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.56 | $-0.50 | +10.7% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.62 | $-0.61 | +1.6% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-0.65 | $-0.67 | -3.1% | ✗ MISS |
Q4 2022 | Nov 2, 2022 | $-0.63 | $-0.58 | +7.9% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.63 | $-0.60 | +4.8% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.57 | $-0.63 | -10.5% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.51 | $-0.45 | +11.8% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.40 | $-0.40 | 0.0% | = MET |
Q3 2021 | Aug 4, 2021 | $-0.39 | $-0.34 | +12.8% | ✓ BEAT |
Latest News
Personalis Announced The Publication Of A New Study In A Journal Of The American Association For Cancer Research, Providing Clinical Evidence That The Company's NeXT Personal, Can Effectively Predict Patient Outcomes Across Various Cancers And Immunotherapy Modalities
📈 PositiveBenzinga•Dec 17, 2025, 11:04 AM
Personalis Publishes Landmark TRACERx Study Showing NeXT Personal Test Detects Lung Cancer Relapse Months Ahead Of Imaging
📈 PositiveBenzinga•Dec 11, 2025, 02:08 PM
Personalis NeXT Personal Dx Breast MRD Recurrence Monitoring Test Receives Medicare Reimbursement Rate of $4,266; Single Plasma Test Set at $1,164 Starting Dec 1, 2025
📈 PositiveBenzinga•Nov 25, 2025, 11:20 AM
Morgan Stanley Maintains Equal-Weight on Personalis, Raises Price Target to $9
📈 PositiveBenzinga•Nov 11, 2025, 04:54 PM
Guggenheim Maintains Buy on Personalis, Raises Price Target to $12
📈 PositiveBenzinga•Nov 11, 2025, 01:57 PM
HC Wainwright & Co. Maintains Buy on Personalis, Raises Price Target to $13
📈 PositiveBenzinga•Nov 11, 2025, 12:10 PM
BTIG Maintains Buy on Personalis, Raises Price Target to $12
📈 PositiveBenzinga•Nov 11, 2025, 10:36 AM
Personalis Announces Medicare Coverage Of Its NeXT Personal Test For Surveillance Of Cancer Recurrence In Breast Cancer
📈 PositiveBenzinga•Nov 10, 2025, 02:07 PM
HC Wainwright & Co. Maintains Buy on Personalis, Raises Price Target to $10
📈 PositiveBenzinga•Nov 6, 2025, 12:08 PM
Personalis shares are trading lower after the company reported Q3 financial results and issued Q4 sales guidance below estimates. Also, the company cut its FY25 sales guidance below estimates.
📉 NegativeBenzinga•Nov 5, 2025, 02:15 PM
Needham Maintains Buy on Personalis, Raises Price Target to $10
📈 PositiveBenzinga•Nov 5, 2025, 11:37 AM
Personalis shares are trading lower after the company reported Q3 financial results and issued Q4 sales guidance below estimates. Also, the company cut its FY25 sales guidance below estimates.
📉 NegativeBenzinga•Nov 4, 2025, 09:50 PM
Personalis Lowers FY2025 Sales Guidance from $70.000M-$80.000M to $68.000M-$73.000M vs $73.150M Est
📉 NegativeBenzinga•Nov 4, 2025, 09:03 PM
Personalis Sees Q4 Sales $15.700M-$20.700M vs $21.769M Est
📉 NegativeBenzinga•Nov 4, 2025, 09:02 PM
Personalis Q3 EPS $(0.24) Beats $(0.28) Estimate, Sales $14.195M Beat $13.307M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:01 PM
BTIG Maintains Buy on Personalis, Raises Price Target to $11
📈 PositiveBenzinga•Oct 22, 2025, 12:16 PM
Personalis Announces Phase 3 LAURA Trial Data With AstraZeneca Showing NeXT Personal MRD Test Effectively Assesses Post-CRT Response In EGFRm Stage III NSCLC
📈 PositiveBenzinga•Oct 16, 2025, 01:08 PM•Also:
Personalis shares are trading higher after the company announced a collaboration with the Yale Cancer Center for a clinical trial titled "A single arm phase II trial of circulating tumor DNA-guided adjuvant therapy with elacestrant in hormone receptor positive HER2 negative breast cancers at risk for late recurrence (CATE)."
📈 PositiveBenzinga•Sep 11, 2025, 03:32 PM•Also:
Personalis And Yale Cancer Center Collaboration For Clinical Trial Titled "A single arm phase II trial of circulating tumor DNA-guided adjuvant therapy with elacestrant in hormone receptor positive HER2 negative breast cancers at risk for late recurrence (CATE),"
📈 PositiveBenzinga•Sep 10, 2025, 08:10 PM
HC Wainwright & Co. Reiterates Buy on Personalis, Maintains $8.5 Price Target
📈 PositiveBenzinga•Sep 8, 2025, 10:58 AM
Frequently Asked Questions about PSNL
What is PSNL's current stock price?
Personalis, Inc. (PSNL) is currently trading at $8.55 per share. The stock has moved +7.89% today.
What is the analyst price target for PSNL?
The average analyst price target for PSNL is $10.67, based on 1 analyst.
What sector is Personalis, Inc. in?
Personalis, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is PSNL's market cap?
Personalis, Inc. has a market capitalization of $0.76 billion, making it a small-cap company.
Does PSNL pay dividends?
No, Personalis, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBFLY
Butterfly Network, Inc.
$3.56
Mkt Cap: $0.9B
CDNA
CareDx, Inc
$19.45
Mkt Cap: $1.0B
CSTL
Castle Biosciences, Inc.
$39.44
Mkt Cap: $1.2B
EVH
Evolent Health, Inc.
$3.99
Mkt Cap: $0.5B
FLGT
Fulgent Genetics, Inc.
$27.61
Mkt Cap: $0.8B
GERN
Geron Corporation
$1.33
Mkt Cap: $0.8B
MRVI
Maravai LifeSciences Holdings, Inc.
$3.43
Mkt Cap: $0.5B
MYGN
Myriad Genetics, Inc.
$6.55
Mkt Cap: $0.6B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
Explore stocks similar to PSNL for comparison